- Home
- TMP vs IMCR Comparison
TMP vs IMCR Comparison
Compare TMP & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TMP | IMCR |
|---|---|---|
| Founded | 1836 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TMP | IMCR |
|---|---|---|
| Price | $100.99 | $33.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $87.00 | $66.33 |
| AVG Volume (30 Days) | 83.7K | ★ 456.6K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 126.16 | 30.39 |
| EPS | ★ 3.86 | 0.23 |
| Revenue | $75,742,000.00 | ★ $249,428,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | $7.94 | $8.21 |
| P/E Ratio | ★ $25.99 | $148.70 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $61.88 | $27.56 |
| 52 Week High | $102.02 | $40.71 |
Technical Indicators
Market Signals| Indicator | TMP | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 54.20 |
| Support Level | $91.10 | $30.95 |
| Resistance Level | $102.02 | $35.73 |
| Average True Range (ATR) | 2.27 | 1.32 |
| MACD | -0.17 | -0.09 |
| Stochastic Oscillator | 81.69 | 53.52 |
Price Performance
Historical ComparisonAbout TMP Tompkins Financial Corporation
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.